These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25969130)

  • 1. Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
    Wainberg ZA; Soares HP; Patel R; DiCarlo B; Park DJ; Liem A; Wang HJ; Yonemoto L; Martinez D; Laux I; Brennan M; Hecht JR
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):61-7. PubMed ID: 25969130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
    Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
    Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
    J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
    Janjigian YY; Vakiani E; Ku GY; Herrera JM; Tang LH; Bouvier N; Viale A; Socci ND; Capanu M; Berger M; Ilson DH
    PLoS One; 2015; 10(8):e0134731. PubMed ID: 26275293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
    Yoon DH; Ryu MH; Park YS; Lee HJ; Lee C; Ryoo BY; Lee JL; Chang HM; Kim TW; Kang YK
    Br J Cancer; 2012 Mar; 106(6):1039-44. PubMed ID: 22343617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
    Almhanna K; Miron ML; Wright D; Gracian AC; Hubner RA; Van Laethem JL; López CM; Alsina M; Muñoz FL; Bendell J; Firdaus I; Messersmith W; Ye Z; Fasanmade AA; Danaee H; Kalebic T
    Invest New Drugs; 2017 Apr; 35(2):235-241. PubMed ID: 28188407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
    Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
    Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
    Lorenzen S; Knorrenschild JR; Pauligk C; Hegewisch-Becker S; Seraphin J; Thuss-Patience P; Kopp HG; Dechow T; Vogel A; Luley KB; Pink D; Stahl M; Kullmann F; Hebart H; Siveke J; Egger M; Homann N; Probst S; Goetze TO; Al-Batran SE
    Int J Cancer; 2020 Nov; 147(9):2493-2502. PubMed ID: 32339253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
    Wang Y; Xu JM; Liu JZ; Lin L; Ge FJ; Li SS; Liu LJ; Zhao CH
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):671-5. PubMed ID: 22340047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
    Valle JW; Armstrong A; Newman C; Alakhov V; Pietrzynski G; Brewer J; Campbell S; Corrie P; Rowinsky EK; Ranson M
    Invest New Drugs; 2011 Oct; 29(5):1029-37. PubMed ID: 20179989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
    Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
    Mackay HJ; Au HJ; McWhirter E; Alcindor T; Jarvi A; MacAlpine K; Wang L; Wright JJ; Oza AM
    Invest New Drugs; 2012 Jun; 30(3):1158-63. PubMed ID: 21400081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
    Ohtsu A; Ajani JA; Bai YX; Bang YJ; Chung HC; Pan HM; Sahmoud T; Shen L; Yeh KH; Chin K; Muro K; Kim YH; Ferry D; Tebbutt NC; Al-Batran SE; Smith H; Costantini C; Rizvi S; Lebwohl D; Van Cutsem E
    J Clin Oncol; 2013 Nov; 31(31):3935-43. PubMed ID: 24043745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
    Petrioli R; Francini E; Roviello F; Marrelli D; Fiaschi AI; Laera L; Rossi G; Bianco V; Brozzetti S; Roviello G
    Cancer Chemother Pharmacol; 2015 May; 75(5):941-7. PubMed ID: 25743995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
    Doi T; Muro K; Boku N; Yamada Y; Nishina T; Takiuchi H; Komatsu Y; Hamamoto Y; Ohno N; Fujita Y; Robson M; Ohtsu A
    J Clin Oncol; 2010 Apr; 28(11):1904-10. PubMed ID: 20231677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.